Abstract: SA-PO0849
Avacopan in Clinical Practice: Adherence, Steroid Reduction, and Other Claims-Based Real-World Outcomes
Session Information
- Glomerular Management: Real-World Lessons and Emerging Therapies
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Zonozi, Reza, International Kidney Vasculitis and Glomerular Center, Fairfax, Virginia, United States
- Pham, Phuong, Amgen Inc, Thousand Oaks, California, United States
- Wallace, Zachary, Amgen Inc, Thousand Oaks, California, United States
- Ibiloye, Elizabeth A., Amgen Inc, Thousand Oaks, California, United States
- Oh, Sam S., Amgen Inc, Thousand Oaks, California, United States
- Byram, Kevin, Vanderbilt University Medical Center, Nashville, Tennessee, United States
Background
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are rare systemic vasculitides that often involve the kidneys. Approved in October 2021, avacopan is an adjunctive therapy for adults with severe active GPA/MPA that works by blocking complement-mediated inflammation.
Methods
This retrospective study used MarketScan® Commercial & Medicare Supplemental claims data to describe demographic/clinical characteristics and medication treatment patterns of adults dispensed avacopan from 10/2021 to 12/2024. Patients must have had continuous insurance plan enrollment ≥12 months (mo) before and ≥3mo after their first avacopan claim (index date), plus a diagnosis for GPA/MPA ±3mo of index. Follow-up began at index and ended with plan disenrollment or end of available data.
Results
Ninety-five eligible patients were included for analysis (Table 1). At baseline, 35.8% of patients had kidney disease and most patients used glucocorticoids (GCs, 95.8%) and rituximab (65.3%). Median (IQR) follow-up and avacopan treatment duration were 381.0 (222.5, 588.5) and 219.0 (109.5, 382.0) days, respectively. Mean prednisone-equivalent daily dose of oral GCs 3mo before index was 16.3mg and decreased to 9.0, 5.3, 5.4 and 3.3mg by 3, 6, 9 and 12mo post-index, respectively. Mean adherence (defined as proportion of days covered, [PDC]) at 12mo post-index was 66.7% and PDC was ≥80% for 51.0% of patients. Among 49 patients with ≥12mo follow-up, 38.8% (n=19) discontinued avacopan by 12mo, with a mean (SD) time to discontinuation of 274.3 (123.0) days.
Conclusion
Kidney disease was frequent among patients with GPA/MPA who were dispensed avacopan. Most patients with ≥12mo follow-up remained on avacopan, and average daily oral GC exposure decreased at 3, 6, 9 and 12mo after avacopan.
Funding
- Commercial Support – Amgen